These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 15627197

  • 1. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM.
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [Abstract] [Full Text] [Related]

  • 2. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
    Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M.
    Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
    [Abstract] [Full Text] [Related]

  • 3. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.
    Clin Exp Rheumatol; 2008 Jan; 26(3):401-7. PubMed ID: 18578960
    [Abstract] [Full Text] [Related]

  • 4. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 5. [Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies].
    Cavazzana I, Franceschini F, Danieli E, Frassi M, Vianelli M, Gorla R, Airò P, Cattaneo R.
    Reumatismo; 2005 Dec; 57(4):267-72. PubMed ID: 16380754
    [Abstract] [Full Text] [Related]

  • 6. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
    Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
    [Abstract] [Full Text] [Related]

  • 7. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
    Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM.
    Rheumatol Int; 2005 Nov; 26(1):58-62. PubMed ID: 15726373
    [Abstract] [Full Text] [Related]

  • 8. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
    Cavazzana I, Bobbio-Pallavicini F, Franceschini F, Bazzani C, Ceribelli A, Bravi E, Zingarelli S, Caporali R, Cattaneo R, Montecucco CM.
    Clin Exp Rheumatol; 2007 Nov; 25(5):676-83. PubMed ID: 18078613
    [Abstract] [Full Text] [Related]

  • 9. Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis.
    Fusconi M, Vannini A, Dall'Aglio AC, Pappas G, Bianchi FB, Zauli D.
    Rheumatol Int; 2007 Nov; 28(1):47-9. PubMed ID: 17564711
    [Abstract] [Full Text] [Related]

  • 10. [TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects].
    Cavazzana I, Bobbio-Pallavicini F, Bazzani C, Bravi E, Zingarelli S, Ceribelli A, Caporali R, Cattaneo R, Franceschini F, Montecucco C.
    Reumatismo; 2006 Nov; 58(4):275-82. PubMed ID: 17216016
    [Abstract] [Full Text] [Related]

  • 11. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
    Aghdashi MA, Khadir M, Dinparasti-Saleh R.
    Curr Rheumatol Rev; 2020 Nov; 16(1):61-66. PubMed ID: 31057111
    [Abstract] [Full Text] [Related]

  • 12. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, Montecucco C.
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL, Cohen PR.
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases.
    Caramaschi P, Bambara LM, Pieropan S, Tinazzi I, Volpe A, Biasi D.
    Joint Bone Spine; 2009 Jul; 76(4):333-42. PubMed ID: 19539516
    [Abstract] [Full Text] [Related]

  • 17. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N.
    Arthritis Res Ther; 2004 Jul; 6(6):R535-43. PubMed ID: 15535831
    [Abstract] [Full Text] [Related]

  • 18. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G, GISEA (Gruppo Italiano per lo Studio delle Early Arthritis).
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [Abstract] [Full Text] [Related]

  • 19. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
    Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D.
    Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
    [Abstract] [Full Text] [Related]

  • 20. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.